近日，港交所官网披露，卓正医疗通过主板上市聆讯，海通国际和浦银国际为联席保荐人。 (编辑：杨燕 林辰) 卓正医疗建立覆盖国内部分发达城市网络，截至2025年10月28日，在国内拥有及经营19家医疗服务机 构，在新加坡、马来西亚有诊所。 （港交所官网披露易） 其战略专注中高端医疗服务市场，目标客户为大众富裕人群，2024年收入计是中国第三大私立中高端综 合医疗服务机构，市场份额2%，在更广泛中高端市场占约0.1%。中国私立中高端医疗服务市场收入 2020 - 2024年复合增长21.9%，预计2024 - 2029年增长14.3%。 ...

在全人医疗方法的指导下，卓正医疗采用了家庭医疗模式，将实体及线上医疗服务融为一体。凭借儿 科、齿科、眼科、皮肤科、耳鼻喉及外科、妇科及内科等一系列专科以及各专科医生之间的密切合作， 公司能够满足患者及其整个家庭的不同医疗需求，从而不断提高患者满意度，并带来跨科室转介的机 会。 智通财经获悉，据港交所12月16日披露，卓正医疗控股有限公司(卓正医疗)通过港交所主板上市聆讯， 海通国际和浦银国际为联席保荐人。 据招股书，卓正医疗一直在战略上专注于服务中高端医疗服务市场，以通常具有较强购买力、偏好更个 性化医疗服务的大众富裕人群为目标客户。根据弗若斯特沙利文的资料，以2024年的收入计，卓正医疗 是中国第三大私立中高端综合医疗服务机构，市场份额为2.0%。 中高端医疗服务是指综合性定制服务，强调患者体验及服务质量，并可进一步分为公立中高端医疗服务 及私立中高端医疗服务。大众富裕人群是指人均年可支配收入超过人民币200,000元的人口群体。于 2024年，私立中高端医疗服务机构占中国中高端医疗服务市场总收入约66.5%及中国医疗服务行业总收 入约5.6%。 另外，根据弗若斯特沙利文的数据，中国私立中高端医疗服务市场的 ...

(文/解红娟 编辑/张广凯） 连续两次IPO折戟让卓正医疗的上市耐心备受考验，为规避2026年底对赌协议到期的风险，这家私立医疗机 构正在紧锣密鼓推进第三次IPO闯关。 近日，卓正医疗再度向港交所递交招股书，由海通国际与浦银国际担任联席保荐人。根据弗若斯特沙利文的 资料，以2024年的收入计，卓正医疗是中国第三大私立中高端综合医疗服务机构，市场份额为2.0%。 在此之前，卓正医疗上市征程已两度遇挫。回溯上市历程，卓正医疗首次闯关始于2024年5月16日，根据港交 所"招股书递交后6个月未完成上市流程自动失效"的规则，该份招股书于当年11月16日按期失效，首次IPO宣 告折戟。2025年3月18日，卓正医疗卷土重来递交第二份招股书，但同样因未能在6个月有效期内完成流程， 于9月18日再度失效。 距离第二份招股书失效不到两个月，卓正医疗再次提交招股书。而卓正医疗之所以对冲刺IPO如此急迫，或 许与前置投资者的对赌协议约束有关。 有媒体报道，招股书明确显示，授予IPO前投资者的赎回权已于本公司首次提交IPO日期前暂停。根据日期为 2025年3月17日的股东协议，仅在本公司的IPO被撤回、拒绝或失效；或2026年12 ...

Core Insights - The private mid-to-high-end healthcare sector in China is experiencing significant growth due to increased disposable income and a shift towards health consumption upgrades [2][3][24] - Zhuozheng Medical has transitioned from losses to profitability, with a notable increase in both net profit and revenue over the past three years [5][6][7] - The company is facing intensified competition as the market becomes more saturated with both domestic and foreign players [28][30] Financial Performance - Zhuozheng Medical's net profit for 2024 is projected to be 80.23 million RMB, marking a turnaround from previous losses [6] - Revenue has surged from 473 million RMB in 2022 to 959 million RMB in 2024, reflecting a compound annual growth rate (CAGR) of 42.3% [7] - The gross margin improved from 9.3% in 2022 to 24% in the first eight months of 2025 [7] Market Position and Strategy - The company targets urban middle-class families with strong self-pay capabilities, a segment that has shown robust growth [7][27] - Zhuozheng Medical operates a network of clinics and small hospitals across major cities, focusing on various specialties including pediatrics, gynecology, dermatology, and dentistry [7][27] - The company plans to use funds from its IPO to expand existing facilities and enter new markets [12] Competitive Landscape - The private healthcare sector is characterized by low concentration, with Zhuozheng Medical ranking third nationally with revenues below 1 billion RMB [25][26] - Major competitors like United Family Healthcare and Jiahui Health hold market shares of 6.8% and 3.2%, respectively, indicating significant room for growth [25][26] - The entry of foreign-owned hospitals and the expansion of public hospital international departments are increasing competitive pressures [28][30] Patient Volume and Service Offerings - The total number of paid patient visits increased from 529,829 in 2022 to 905,825 in 2024, with a strong growth trajectory continuing into 2025 [13][15] - The average cost per visit has risen, with dermatology services commanding the highest fees, reflecting the premium nature of the services offered [15][17] - Zhuozheng Medical has introduced a membership program to enhance customer loyalty, although it currently contributes only a small percentage to overall revenue [15] Industry Trends - The number of private healthcare institutions in China is expected to grow from 483,000 in 2020 to 554,300 by 2024, while public institutions are projected to decline [24] - The proportion of the "mass affluent" population, defined as those with disposable incomes exceeding 200,000 RMB, is increasing, providing a larger customer base for private healthcare services [3][27] - Policy support for private healthcare is strengthening, with government initiatives aimed at attracting foreign investment and increasing service supply [4][27]

Company Overview -卓正医疗控股有限公司 has submitted its third listing application to the Hong Kong Stock Exchange, with Haitong International and浦银国际 as joint sponsors [1] - As of 2024,卓正医疗 is the third largest private mid-to-high-end comprehensive medical service provider in China, holding a market share of 2.0% [3] - The company operates 19 medical service institutions in China, including 17 clinics and 2 hospitals, and has expanded to Singapore and Malaysia [3] Business Model and Strategy -卓正医疗 focuses on the mid-to-high-end medical service market, targeting affluent consumers who prefer personalized healthcare [3] - The company employs a family medical model that integrates physical and online medical services, resulting in a growing patient base [4] -卓正医疗 plans to expand its network through organic growth and strategic acquisitions, aiming to penetrate more new first-tier cities [3] Financial Performance - Revenue has shown a consistent upward trend, with figures of RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024, with RMB 614.8 million reported for the first eight months of 2025 [8] - The company recorded net losses of RMB 222 million in 2022 and RMB 353 million in 2023, but achieved net profits of approximately RMB 80.2 million in 2024 and RMB 83.2 million in the first eight months of 2025 [9] - Gross profit margin increased from 9.3% in 2022 to 23.6% in 2024, attributed to improved operational efficiency and increased patient visits [10] Market Overview - As of 2024, there are 1.092 million medical service institutions in China, with private institutions growing at a compound annual growth rate (CAGR) of 3.5% from 2020 to 2024 [12] - The revenue of private medical service institutions in China is projected to grow from RMB 676 billion in 2020 to RMB 1.292 trillion in 2024, with a CAGR of 17.6% [12] - The number of paid patient visits to private medical institutions increased from 1.157 billion in 2020 to 1.577 billion in 2024, with expectations for further growth [13] Competitive Advantages -卓正医疗's competitive advantages include high brand recognition, a growing patient base through its integrated service model, and a stable team of highly qualified doctors [5] - The company has a centralized, standardized, and digital management system, along with early adoption of artificial intelligence technology to enhance service quality and operational efficiency [5] Governance and Management - The board of卓正医疗 consists of 11 members, including two executive directors and four independent non-executive directors, responsible for business management and operations [15] - The company has attracted significant investment from institutions such as Tencent and富德生命人寿, with Tencent holding 19.39% of the shares [19]

Core Viewpoint - Distinct Healthcare Holdings Limited (卓正医疗控股有限公司) has achieved profitability in 2024 after previously incurring losses, indicating a positive turnaround in its financial performance [4]. Group 1: Company Overview - Established in 2012, Distinct Healthcare focuses on the mid-to-high-end private healthcare market in China, operating 20 medical service institutions across major cities [2]. - As of March 10, 2025, the company has expanded its services to Singapore, with three general clinics [2]. - According to Frost & Sullivan, Distinct Healthcare ranks as the third-largest private mid-to-high-end healthcare service provider in China based on 2023 revenue [2]. Group 2: Patient Metrics - The total number of patients served at Distinct Healthcare's facilities in China increased from 162,393 in 2022 to 242,549 in 2024 [3]. - The total paid patient visits across all services, including online platforms, rose from 529,829 in 2022 to 905,825 in 2024 [3]. - The patient retention rate improved from 75.7% in 2022 to 80.0% in 2024, indicating enhanced customer loyalty [3]. Group 3: Financial Performance - Revenue figures for Distinct Healthcare from 2022 to 2024 were 473 million yuan, 690 million yuan, and 959 million yuan, respectively, reflecting a compound annual growth rate (CAGR) of 42.3% [3]. - The gross profit margin increased from 9.3% in 2022 to 23.6% in 2024, showcasing improved operational efficiency [3]. - The adjusted net loss decreased from 123 million yuan in 2022 to 4.3 million yuan in 2023, with a shift to an adjusted net profit of approximately 10.7 million yuan in 2024 [4]. Group 4: Investment and Valuation - Distinct Healthcare has attracted investments from notable institutions, including Tencent, which holds a 19.39% stake, making it the largest institutional investor [5][4]. - Prior to its IPO, the company's valuation was approximately 510 million USD following its last financing round in 2021 [6].

Core Viewpoint - New Century Healthcare (01518.HK) has issued a profit warning, expecting a loss attributable to shareholders between RMB 60 million and 70 million for the six months ending June 30, 2025, marking a significant decline from a net profit of RMB 25.2 million in the same period of 2024 [1][3]. Financial Performance - The company reported a revenue decline of 9.28% to RMB 846 million in 2024, with net profit plummeting by 43.71% to RMB 47.38 million, and a decrease in gross margin from 43.63% in 2023 to 40.75% [3]. - The shift from profit to loss in the first half of 2025 is attributed to reduced demand for pediatric and obstetric services, impairment losses on goodwill and other long-term assets, and the reversal of deferred tax assets [3]. Regulatory Issues - New Century Healthcare and several directors faced disciplinary action from the Hong Kong Stock Exchange due to violations related to connected transactions, resulting in a loss of over RMB 100 million [4]. - The Hong Kong Stock Exchange has mandated the company to conduct an independent internal review, and all involved directors are required to undergo training [4]. Company Overview - New Century Healthcare is a private medical group focused on providing high-quality medical services to children and women, with its first hospital established in 2002 and officially operating since 2006 [7].

将在京津、上海及大湾区扩大服务规模。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，3月14日，和睦家医疗宣布获华平投资增持股权，双方深化战略合作。 3月13日，复星医药（600196.SH）发布公告，其子公司复星实业拟以1.24亿美元现金对价向华平 投资旗下的Calcite Gem转让其所持有的标的公司940万股普通股，约占标的公司股份总数的 6.6%，交易对应的每股单价为13.2美元。标的公司主要资产系其通过控股子公司新风医疗集团NFH （下称"新风医疗"）持有及运营的和睦家医院和诊所。 本次交易完成后，华平投资将成为和睦家医疗的重要股东并获董事会席位 ，复星医药将彻底退出和 睦家医疗股东结构。此次合作升级彰显了华平投资对和睦家医疗发展战略的信心，将进一步帮助和睦 家医疗确立其在中国私立医疗产业中的领先地位。交易完成后，华平投资将成为和睦家医疗的重要股 东并获董事会席位。 华平投资合伙人、中国私募股权投资联席总裁方敏 表示："华平投资高度认可和睦家医疗所拥有的独 特优势以及过去几年所取得的成绩。我们很高兴此次增持和睦家医疗，未来也将继续支持公司发展， 力争用 ...